Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:13:48.058Z.
Calculation as of: 2026-10-06T17:13:48.058Z.
Quote observation: 2026-10-06T17:10:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 65e01e2061821370315a71c231e2ba412a336584d38d2dbcbde0d0d1c3e2cd16
PE RATIO
N/A
Mobia Medical, Inc. Common Stock
Market Cap
$302.91M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $302.91M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $301.04M | N/A | 396.83 | 396.83 | 396.83 |
| C4 Therapeutics, Inc. (CCCC)vs › | $314.01M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $293.04M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $289.02M | N/A | N/A | N/A | N/A |
| Sagimet Biosciences Inc. (SGMT)vs › | $287.16M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.48M | N/A | 16.56 | 19.39 | 19.39 |
| Avita Medical Inc. (RCEL)vs › | $321.51M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $322.03M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.61M | N/A | 6.29 | 6.29 | 6.29 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$9.11
Forward EPS (Est.)
$-2.95
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
